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 Introduction 
 Sunburn is an ultraviolet B (UVB)-induced phenom-
enon and represents one of the initial cornerstones in the 
pathogenesis of malignant melanoma and nonmelanoma 
skin cancer  [1, 2] . Hence, photoprotection and sun avoid-
ance are of capital importance in the fight against skin 
cancer. Patients who have had a melanoma, squamous 
cell carcinoma, or basal cell carcinoma are at risk of vita-
min D deficiency due to the recommendation of sun 
avoidance, and vitamin D supplementation is common 
practice in this patient population. However, vitamin D 
should be given upstream since it could have a preventive 
role in carcinogenesis. Indeed, previous studies have 
found that vitamin D supplementation or higher vitamin 
D serum levels may be associated with a reduced inci-
dence  [3] or a better prognosis of skin cancer, respective-
ly  [4] . Moreover, solar radiation, via the vitamin D syn-
thesized in the skin, may have a beneficial influence on 
both the incidence and the outcome of melanoma  [5] . 
However, thorough epidemiologic evidence that ade-
quate vitamin D supplementation or solar exposure pro-
tects against nonmelanoma skin cancer  [6] and melano-
ma  [3, 5, 7] is lacking.
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 Abstract 
 Background: Whether vitamin D supplementation allevi-
ates the severity of ultraviolet B (UVB)-induced erythema 
and/or facilitates its resolution remains undetermined.  Ob-
jective: To study the effect of oral vitamin D on UVB-induced 
erythema and its resolution in fair-skinned subjects.  Meth-
ods: UVB-induced erythema was quantified using a Chroma 
Meter ® in 50 volunteers 48 h before and 10 days after the 
random administration of 200,000 IU vitamin D (n = 40) or 
placebo (n = 10). Resolution of erythema in both groups was 
assessed by chromametry 24, 48, and 72 h after vitamin D 
administration.  Results: No statistical difference between 
erythema values before and after administration in the vita-
min D-supplemented group (p = 0.44) or the placebo group 
(p = 0.34) was noted. No statistical difference was evident 
between both groups with respect to resolution of erythema 
(p = 0.30).  Conclusion: Oral vitamin D supplementation nei-
ther improves protection against UVB-induced erythema 
nor facilitates its resolution.  © 2015 S. Karger AG, Basel 
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 Vitamin D displays a high number of in vitro photopro-
tective properties. Calcitriol [1α,25-dihydroxyvitamin D 3 
or 1,25(OH) 2 D 3 ] may enhance keratinocyte  [8–13] , mela-
nocyte  [13] and fibroblast  [10, 13] survival after UVR ex-
posure by reducing UV-induced promutagenic DNA 
damage like cyclobutane pyrimidine dimers  [8–13] , 
8-oxo-7,8-dihydro-2-deoxyguanosine  [9, 14] , 3-nitrotyro-
sine, and 8-nitroguanosine  [9, 15, 16] , which are mutagen-
ic  and are markers of inflammation and carcinogenesis. 
Moreover, 1,25(OH) 2 D 3 could also influence the upregula-
tion of p53, allowing improvement of DNA repair  [13] .
 Whether these in vitro results on photoprotection are 
clinically relevant and whether eventual photoprotective 
effects are influenced by the vitamin D serum status re-
main undetermined. 
 This pilot study evaluated whether oral vitamin D sup-
plementation in fair-skinned healthy individuals affects 
the severity of UVB-induced erythema and facilitates its 
resolution.
 Materials and Methods 
 This pilot study was performed in accordance with the Hel-
sinki Protocol (2000) and was approved by the University Hospital 
Ethics Committee. All study procedures were explained to the vol-
unteers. All participants signed an informed consent form. The 
sequence of this study is presented in  table 1 . 
 Patients 
 Fifty phototype III [Fitzpatrick’s classification type III: fair to 
matt skin, sometimes burns, always tans (medium tan), a few 
freckles] young healthy volunteers (males: n = 21, females: n = 29, 
mean age 22.3 ± 1.9 years, BMI 21.3 ± 1.96) were invited to par-
ticipate in this study. They comprised a homogenous population 
in order to reduce the influence of some variables (BMI, age, and 
no vitamin D supplementation  [17] ) on vitamin D production. 
This study was performed in November to minimize natural UVB 
exposure. The exclusion criteria were as follows: oral vitamin D 
supplementation, age <18 or >26 years, BMI <18 or >25, a high 
dietary intake of vitamin D, pregnancy, lactation, skin disease, im-
munosuppression, photosensitizing drug intake, photosensitizing 
disease, liver insufficiency, PUVA or UVB therapy, and recent hol-
idays in the sun or sunbed less than 1 month prior to baseline use.
 UVB Erythema Induction 
 A standardized UVB-induced erythema was induced on days 1 
and 14 using the Gigatest ® UVB-MED Tester UVB-311 (narrow-
band, 310–315 nm; Medisun ® , Brühl, Germany) ( table  1 ). The 
Medisun Gigatest MED displays 5 test fields, each with a diameter 
of 15 mm. The 5 dose levels vary from 100 to 13% and are obtained 
through special high-value coated filters. UVB-induced erythema 
is a recognized marker for cutaneous inflammation and it is a valu-
able tool as an indirect marker for increased skin cancer risk  [7] . 
The UVB energy output in the 100% transmission field averages 4 
mW/cm 2 . The 100% transmission field was used for the colorimet-
ric evaluation as this field was the only field visible with the naked 
eye in all of the patients on day 3. The Gigatest was applied verti-
cally on each subject’s right lower back using an irradiation time 
of 2.5 min for all subjects, equivalent to 0.6 J/cm 2 , for 100% trans-
mission. About 30 min after irradiation, patients were examined 
at the test site to exclude solar urticaria.
 Minimal Erythema Dose Evaluation 
 A minimal erythema dose (MED) test was performed 24 h after 
Medisun Gigatest UVB exposure. The number of positive fields 
visible with the naked eye was evaluated over a total of 5 test fields. 
 Chroma Meter ® Erythema Evaluation 
 Chroma Meter CR400 (Konica Minolta, Japan) evaluations of 
the a * parameter according to the L * a * b * mode (CIE 1976, +a/–a: 
red/green axis, +b/–b: yellow/blue axis, L: lightness) are a well-rec-
ognized and validated technique for measuring variations in UVB-
induced erythema  [18, 19] . Measurements of the a * values of the 
UVB-induced erythemas were performed in triplicate. The perile-
sional skin served as a control (C) and its a * value was measured in 
triplicate. To eliminate interobserver variation, all evaluations were 
performed by the same investigator under standardized illumina-
tion of the study room and positioning of the subject and investiga-
tor, as well as at a constant temperature. Chroma Meter measure-
ments were performed on day 2 and on days 15, 16, and 17 ( table 1 ). 
The difference in erythema intensity in interventional studies is a 
common measure to evaluate in vivo photoprotection  [20] . 
 25(OH)D Analysis 
 Blood samples were collected on days 1 and 14 ( table 1 ). The 
samples were tested using a MassChrom ® 25-OH-Vitamin D 3 /D 2 
LC-MS/MS kit with a 3-epi-25-OH-Vitamin D 3 upgrade (LCMS; 
Gräfelfing, Germany) on the AB SCIEX QTRAP ® 5500 system 
(AB SCIEX; Framingham, Mass., USA). This LC-MS/MS is trace-
able to the National Institute of Standards and Technology (NIST) 
reference material SRM 2972 and the ID-LC-MS/MS 25(OH)D 
reference method procedure. The upgrade procedure allows 
25(OH)D 3 and 25(OH)D 2 to be separated from their epimeric 
form 3-epi-25-(OH)-D. The coefficient of variation was <2%. All 
samples were measured in duplicate.
 Oral Vitamin D Supplementation 
 Two oral doses of 100,000 IU equivalent to 200,000 IU of cho-
lecalciferol (n = 40) and placebo (n = 10), identical in color and 
consistency, were simultaneously administered in liquid form at 
 Table 1.  Study flow chart
Visit  Day
 1 2 4 14 15 16 17
Induction of UVB erythema X X
Vitamin D serum status X X
Colorimeter (a*-C) X X X X
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random to the volunteers on day 4 under the supervision of one of 
the investigators in a blinded manner. The dose of 200,000 IU of 
vitamin D and collection of blood sample 10 days after administra-
tion were chosen according to the results of oral vitamin D supple-
mentation tests showing peak levels between 7 and 15 days  [21] .
 Endpoints 
 The main outcomes were as follows: (1) mean increase in 
25(OH)D after oral vitamin D supplementation (n = 40) versus 
placebo (n = 10); (2) erythema intensity expressed as (a * -C) on day 
15 versus (a * -C) on day 2 in the placebo (n = 10) and vitamin D-
supplemented group (n = 40), respectively; (3) alleviation of ery-
thema expressed as the area under the curve (AUC), defined as the 
total (a * -C) values on days 15, 16, and 17 in the placebo (n = 10) 
versus the vitamin D-supplemented group (n = 40); (4) photopro-
tection as assessed by the median number of visible test fields (24 
h after Gigatest UVB testing) on day 15 versus day 2, and (5) ery-
thema alleviation expressed as the mean number of visible test 
fields on days 15, 16, and 17 in the placebo group and the vitamin 
D-supplemented group.
 Statistical Analysis 
 Data are expressed as means ± SD. A paired Student t test was 
used to compare increases in 25(OH)D after oral vitamin D sup-
plementation and to compare the changes in (a * -C) on day 15 ver-
sus day 2. The Student t test was used to compare (a * -C) and AUC 
values between the two groups.
 p < 0.05 was considered statistically significant. Calculations 
were performed using SAS version 9.3 software (SAS Institute, 
Cary, N.C., USA) and  figures 1–3 were drawn using S-PLUS ver-
sion 8.1 software.
 Results 
 There was no statistically significant difference in 
25(OH)D levels before and after placebo administration 
in the control group (mean 27.3 ± 11.5 vs. 25.0 ± 10.6 ng/
ml, respectively, p = 0.17). A statistically significant in-
crease was observed in the vitamin D supplementation 
group between days 1 and 14 (mean 24.6 ± 9.4 vs. 48.7 ± 
12.3 ng/ml, respectively, p < 0.0001). The increase in 
25(OH)D levels differed significantly between the two 
groups (p < 0.0001;  fig. 1 ).
 There was no statistically significant difference in the 
mean (a * -C) values measured 24 h after UVB-induced 
erythema before and after vitamin D supplementation
(n = 40; 11.4 ± 2.9 on day 2 vs. 11.1 ± 2.8 on day 15, p = 
0.53), nor was there any statistically difference in the 
mean (a * -C) values measured 24 h after UVB-induced 
erythema before and after placebo administration (n = 10; 
mean 9.7 ± 3.8 on day 2 and 10.9 ± 3.5 on day 15, p = 0.25). 
There was no statistically significant difference between 
supplemented volunteers and placebo subjects with re-
spect to erythema values 24 h after UVB erythema induc-
tion on day 15 (p = 0.19). 
 The mean AUC values were 580 ± 176 in the placebo 
group and 524 ± 147 in the vitamin D-supplemented 
group, but these were not statistically significantly differ-
ent (p = 0.30;  fig. 2 ). The temporal evolution of (a * -C) 















































 Fig. 1. Vitamin D serum levels of the placebo and vitamin D-sup-
plemented groups on days 1 and 14 (individual values presented 
as means ± SE). 
 Fig. 2. AUC values of UVB-induced erythema in the placebo and 
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 figure 3 (placebo mean at 24, 48, and 72 h: 10.88, 12.76, 
and 11.95, respectively; vitamin D mean at 24, 48, and
72 h: 11.06, 10.88, and 10.81, respectively). 
 The median number of visible test fields at 24 h was 4 
(minimum 1, maximum 4, mean 3.6; n = 50), which was 
equivalent to 0.195 J/cm 2 , equivalent to the median MED. 
The mean number of visible test fields was 3.5 and 3.63 in 
the placebo and vitamin D-supplemented groups, respec-
tively, on day 2 versus 3.6 in the placebo group on day 15 
(n = 10), and 3.83 in the vitamin D-supplemented group 
(n = 40). These differences were not statistically signifi-
cant (p = 0.59).
 Erythema alleviation was also expressed as the mean 
number of visible test fields on days 15, 16, and 17. The 
mean number of visible test fields in the placebo group 
was 3.6, 3, and 2.8 versus 3.83, 3.5, and 3 in the vitamin 
D-supplemented group on days 15, 16, and 17, respec-
tively. These differences were not statistically significant. 
 Discussion 
 The in vivo effects of vitamin D on the reduction of 
UVB-induced erythema remain unclear. Several studies 
have examined the clinical effect of topical calcitriol  [22] 
or calcipotriol  [23–26] on the MED in humans, and the 
results are contradictory. Calcipotriol is a synthetic de-
rivative of calcitriol and it is known to display similar 
properties in terms of epidermal proliferation, modula-
tion of keratinization, and inflammation  [25] . The delay 
between topical application and UV irradiation varies 
among studies, potentially influencing the MED. In brief, 
calcipotriol 0.005%  [23–27] applied 15–20 min  [25, 27] or 
immediately before  [23, 24, 26] irradiation, with a thick 
enough layer  [23] , influenced the MED  [23–27] , which 
could reach an increase of 31%  [27] or an increase from 
22.6 to 54.6 mJ/cm 2  [23] . Two hours after application, the 
MED returned to baseline  [26] . In contrast, when calcitri-
ol or calcipotriol was applied 24  [22] , 12  [23] , or 2 h before 
 [24] or immediately after  [22] irradiation, there was no 
influence on the UVB-induced erythema  [22–24] . Never-
theless, when applied directly after UV exposure, it de-
creased the density of sunburn cells and the number of 
thymine dimers  [16, 22] . This suggests that the in vitro 
results do not necessarily correlate with an increase in 
MED  [22] . 
 Vitamin D also displays immunoregulatory proper-
ties. The immune effects of calcitriol on in vivo human 
skin are as yet unspecified  [22] . Dietary vitamin D pro-
duced a reduction in DNA damage, in cutaneous inflam-
mation, and in immunosuppression after UVB irradia-
tion in a murine model  [28] . This could mean that vita-
min D counteracts the inhibitory effects of UVB on 
cutaneous immunity  [29] and could be involved in im-
munomodulation  [11] . Interestingly, in humans, UV-in-
duced suppression of a delayed-type hypersensitivity re-
action was measured after topical application of calcitriol 
but it failed to prevent UV-induced immunosuppression 
 [22] . These controversial results can be explained by the 
differing immune properties of calcitriol in mice and hu-
mans and could be dose related, with protective immune 































 Fig. 3. Temporal evolution of (a * -C) values 
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sorption and greater dose relative to body weight in the 
mouse)  [22] . The in vitro immunosuppressive properties 
of 1,25(OH) 2 D 3 are dependent on genomic pathways and 
include, among others, inhibition of dendritic cell differ-
entiation and maturation, inhibition of the production of 
numerous cytokines  [30] or T cell proliferation  [31] and 
polarization from a Th1 and Th17 phenotype towards a 
Th2 phenotype  [32] . A recent analysis showed that vita-
min D modulates tumor suppression via a mechanism 
that depends on the amount of vitamin D receptor in the 
skin  [33] .
 This pilot study revealed that high-dose oral vitamin 
D supplementation does not have an impact on the sever-
ity of a fixed-dose UVB-induced erythema. The mean se-
rum level of cholecalciferol achieved in our study reached 
48.7 ± 12.3 ng/ml but may, however, not have been 
enough to observe any photoprotective effects. Further-
more, there was no improvement or acceleration in the 
resolution of UVB-induced erythema in the supplement-
ed group and no difference in visual MED in the vitamin 
D versus placebo groups. These results imply that oral 
vitamin D supplementation is probably of no use as pro-
tective oral therapy against sunburn or as a preventive 
technique to increase the healing speed of sunburn. It 
may be that any subtle antierythema effect of vitamin D 
is only observable at the threshold of erythema and not 
with supra-MED doses. Indeed, although the groups were 
all skin type III, they likely had a reasonable range of 
MED, and so using the highest dose in all participants 
may have resulted in missing some anti-inflammatory ef-
fects at the erythema threshold. Moreover, Chroma Me-
ter measurements were not taken at each participant’s 
MED site, but this was in order to still be able to have a 
measurable residual erythema on day 17, equaling 72 h 
after induction. Interestingly, using a fluorescent lamp 
with an emission spectrum of 280–350 nm and a peak of 
310–315 nm, it has been observed that calcitriol  [34] and 
calcipotriol  [25] have photoprotective actions against 
UVB-induced reduction of the viability of cultured kera-
tinocytes  [34] or of DNA synthetic activity  [25] in certain 
UVB dose ranges, but this was not observed beyond 50 
mJ/cm 2 or 60 mJ/cm 2 , respectively. This would imply that 
calcitriol and calcipotriol are photoprotective only at low-
er doses of UVB radiation. Thus, the importance of vita-
min D for photoprotection should no be overlooked. In 
the skin, mechanisms of endogenous photoprotection 
following sun exposure include, among others, increased 
pigmentation via melanocytes and increased cornifica-
tion of keratinocytes. It has been previously reported that 
calcitriol could enhance these processes  [35] . Vitamin D 
can be converted to 1,25(OH) 2 D 3 due to the presence of 
vitamin D-25 hydroxylase and 25(OH)D-1α-hydroxylase 
in keratinocytes  [7] , though the process takes several 
hours. This suggests that formation of 1,25(OH) 2 D 3 in 
the skin seems to protect against the next rather than the 
initial UV irradiation  [12] , implying that exogenous ana-
logues of calcitriol could represent an added value in sun-
screens  [35] .
 In brief, oral vitamin D supplementation in fair-
skinned healthy individuals does not improve direct 
UVB-induced erythema, and secondly single, high-dose, 
oral supplementation does not reduce the severity of 
acute UVB-induced inflammation. Hence, oral vitamin 
D supplementation may not be useful in reducing UVB-
induced sunburn but it should not be omitted in the glob-
al approach against vitamin D deficiency and skin cancer 
given its antiproliferative effects, prodifferentiation ac-
tions, and inhibitory effects on the migration, invasion, 
and metastasis of skin cancer  [7, 36] .
 Conclusion 
 The results of this pilot evaluation suggest that oral, 
single, high-dose vitamin D supplementation does not 
improve protection against acute UVB-induced erythe-
ma or facilitate its resolution in fair-skinned subjects. The 
role of oral supplementation of vitamin D in the preven-
tion of skin cancer merits further investigation in order 
to evaluate the clinical relevance of its beneficial photo-
protective in vitro properties.
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